(Q53401310)

14 May 2018

title

Immunopathological features of human pulmonary tumors following low-dose interleukin-2. (English)

1 reference

14 May 2018

author name string

S G Swisher

1

1 reference

14 May 2018

T M Anderson

2

1 reference

14 May 2018

D R Wen

3

1 reference

14 May 2018

M A Stene

4

1 reference

14 May 2018

A J Cochran

5

1 reference

14 May 2018

S H Golub

6

1 reference

14 May 2018

E C Holmes

7

1 reference

14 May 2018

publication date

1 January 1991

1 reference

14 May 2018

Cancer Immunology, Immunotherapy

published in

1 reference

14 May 2018

volume

33

1 reference

14 May 2018

issue

5

1 reference

14 May 2018

page(s)

327-332

1 reference

14 May 2018

https://scigraph.springernature.com/pub.10.1007/bf01756598

exact match

0 references

cites work

The use of avidin-biotin interaction in immunoenzymatic techniques

1 reference

https://api.crossref.org/works/10.1007%2FBF01756598

Possible host resistance in carcinoma of the breast: a histological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01756598

Intraperitoneal administration of interleukin-2 in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01756598

Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01756598

Characterization of activated lymphocytes in colon cancer

21 January 2018

1 reference

12 December 2020

Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer

1 reference

12 December 2020

Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells

1 reference

12 December 2020

Inhibition of DNA synthesis by a small-cell lung carcinoma-derived protein

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method

1 reference

12 December 2020

Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content

1 reference

12 December 2020

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1 reference

12 December 2020

Histology and prognosis in malignant melanoma

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.

1 reference

12 December 2020

Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes

1 reference

12 December 2020

The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

The role of transferrin in natural killer cell and IL-2-induced cytotoxic cell function

1 reference

12 December 2020

Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors

1 reference

12 December 2020

Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera

1 reference

12 December 2020

Successful therapy of natural killer-resistant pulmonary metastases by the synergism of gamma-interferon with tumor necrosis factor and interleukin-2 in mice

1 reference

12 December 2020

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

12 December 2020

Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans

1 reference

12 December 2020

Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro

1 reference

12 December 2020

Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha

1 reference

12 December 2020

Presence of immunosuppressive factors in brain-tumor cyst fluid.

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

A method for improved yield and purity in extracting lymphocytes from lung tumors

1 reference

12 December 2020

The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.

1 reference

12 December 2020

Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

Generation of lymphokine-activated killer cell activity from human thymocytes

1 reference

12 December 2020

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

1 reference

12 December 2020

Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2

1 reference

12 December 2020

TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01756598

1 reference

14 May 2018

1 reference

14 May 2018